(2024) developed a tumor-targeted delivery platform utilizing tumor-derived extracellular vesicles (TEVs) to co-deliver small interfering RNA against STAT3 (siSTAT3) and the chemotherapeutic agent doxorubicin (DOX), termed siSTAT3-DOX@TEV. This evidence concerns the gene STAT3 and neoplasm.